An oral hypoglycemic compound for use in the treatment of diabetes mellitus having the general formula ##SPC1## And which is one of the group consisting of: A. the compound wherein R.sub.1 is an aliphatic series containing 2 to 8 carbon atoms; B. the compound wherein R.sub.2 = R.sub.3 and is a member of the group consisting of hydrogen, aliphatic, and aromatic radicals; and C. the compound wherein X represents an amino or a substituted amino radical. The compound is prepared by synthesizing p-amino benzenesulfonamide through the chlorsulfonation of acetanilide and placing a radical group in the para position of the benzene ring. The compound may be incorporated with therapeutically acceptable carriers to make compositions adapted to be administered orally in the treatment of diabetes mellitus. The compound is intended to aid in the regulation of metabolic disturbance in diabetes mellitus not only by stimulating the production and release of insulin but also by functioning as a substitute for insulin in this regulatory process.
Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase using substituted carbamimidothioic acid phenylalkyl esters.
The present invention relates to the use of biguanide derivatives of general formula I below: ##STR00001## in which: the groups R1 and R2 represent, independently of each other, a hydrogen atom, a C.sub.1 C.sub.7, alkyl group, a cycloalkyl group, a heterocycle, a C.sub.2 C.sub.7 alkenyl group, an aryl group, an aralkyl group, an aryloxyalkyl group or a heteroaryl group, or R1 and R2, taken together, represent a C.sub.2 C.sub.7 alkylene which may contain one or more hetero atoms, and the group R3 represents a primary, secondary or tertiary amine, or pharmaceutically acceptable salts thereof, to manufacture a medicinal product with cicatrizing action, the said medicinal product being in a pharmaceutical form for topical use.
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may "activate" the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin polypeptide-oligomer conjugate of formula V ##STR00001## to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may "activate" the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.
